Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    December 2017
  1. PONTI G, Manfredini M, Greco S, Pellacani G, et al
    BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.
    Anticancer Res. 2017;37:7043-7048.
    PubMed     Text format     Abstract available


  2. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Text format     Abstract available


  3. DELGADO AF, Delgado AF
    Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:6825-6829.
    PubMed     Text format     Abstract available


  4. WOZNIAK M, Peczek L, Czernek L, Duchler M, et al
    Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions.
    Anticancer Res. 2017;37:6779-6789.
    PubMed     Text format     Abstract available


  5. YANAROJANA M, Nararatwanchai T, Thairat S, Tancharoen S, et al
    Antiproliferative Activity and Induction of Apoptosis in Human Melanoma Cells by Houttuynia cordata Thunb Extract.
    Anticancer Res. 2017;37:6619-6628.
    PubMed     Text format     Abstract available


  6. BERUS T, Halon A, Markiewicz A, Orlowska-Heitzman J, et al
    Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review.
    Anticancer Res. 2017;37:6541-6549.
    PubMed     Text format     Abstract available


    November 2017
  7. MA YS, Hsiao YT, Lin JJ, Liao CL, et al
    Phenethyl Isothiocyanate (PEITC) and Benzyl Isothiocyanate (BITC) Inhibit Human Melanoma A375.S2 Cell Migration and Invasion by Affecting MAPK Signaling Pathway In Vitro.
    Anticancer Res. 2017;37:6223-6234.
    PubMed     Text format     Abstract available


  8. NAJEM A, Krayem M, Perdrix A, Kerger J, et al
    New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
    Anticancer Res. 2017;37:5941-5953.
    PubMed     Text format     Abstract available


    October 2017
  9. PSINAKIS F, Katseli A, Koutsandrea C, Frangia K, et al
    Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.
    Anticancer Res. 2017;37:5719-5726.
    PubMed     Text format     Abstract available


  10. HU WP, Kuo KK, Senadi GC, Chang LS, et al
    Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells.
    Anticancer Res. 2017;37:5499-5505.
    PubMed     Text format     Abstract available


  11. GARMPIS N, Damaskos C, Garmpi A, Dimitroulis D, et al
    Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Anticancer Res. 2017;37:5355-5362.
    PubMed     Text format     Abstract available


    September 2017
  12. USLU U, Schliep S, Schliep K, Erdmann M, et al
    Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Anticancer Res. 2017;37:5033-5037.
    PubMed     Text format     Abstract available


  13. SUCKOW MA, Wolter WR, Duffield GE
    The Impact of Environmental Light Intensity on Experimental Tumor Growth.
    Anticancer Res. 2017;37:4967-4971.
    PubMed     Text format     Abstract available


    August 2017
  14. KIM YJ, Song SY, Kim W, Jeong SY, et al
    Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma.
    Anticancer Res. 2017;37:4239-4246.
    PubMed     Text format     Abstract available


    July 2017
  15. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Text format     Abstract available


  16. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Text format     Abstract available


  17. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Text format     Abstract available


  18. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Text format     Abstract available


    June 2017
  19. USLU U, Erdmann M, Schliep S, Dorrie J, et al
    Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.
    Anticancer Res. 2017;37:3243-3248.
    PubMed     Text format     Abstract available


  20. JANIK ME, Szlezak D, Surman M, Golas A, et al
    Diversified beta-2-adrenergic Receptor Expression and Action in Melanoma Cells.
    Anticancer Res. 2017;37:3025-3033.
    PubMed     Text format     Abstract available


  21. LAUBE F, Glanz D
    Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells.
    Anticancer Res. 2017;37:3001-3007.
    PubMed     Text format     Abstract available


    April 2017
  22. YAMAUCHI K, Mitsunaga T, Afroze SH, Uddin MN, et al
    Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells.
    Anticancer Res. 2017;37:1575-1579.
    PubMed     Text format     Abstract available


    March 2017

  23. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed     Text format    


  24. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Text format     Abstract available


  25. LAWSON BO, Khong HT
    Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Anticancer Res. 2017;37:1365-1368.
    PubMed     Text format     Abstract available


  26. SPILIOPOULOS K, Peschos D, Batistatou A, Ntountas I, et al
    Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area.
    Anticancer Res. 2017;37:1113-1120.
    PubMed     Text format     Abstract available


    February 2017
  27. RYU SH, Heo SH, Park EY, Choi KC, et al
    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res. 2017;37:607-614.
    PubMed     Text format     Abstract available


    January 2017
  28. SEHMISCH L, Schild SE, Rades D
    Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.
    Anticancer Res. 2017;37:249-252.
    PubMed     Text format     Abstract available


  29. FORTIS SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, et al
    Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Anticancer Res. 2017;37:143-148.
    PubMed     Text format     Abstract available


  30. NGUYEN AH, Detty SQ, Agrawal DK
    Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Anticancer Res. 2017;37:1-7.
    PubMed     Text format     Abstract available


    December 2016
  31. RADES D, Sehmisch L, Janssen S, Schild SE, et al
    Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.
    Anticancer Res. 2016;36:6637-6640.
    PubMed     Text format     Abstract available


  32. NAFFOUJE SA, Naffouje R, Chen J, Salti GI, et al
    Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor.
    Anticancer Res. 2016;36:6603-6610.
    PubMed     Text format     Abstract available


  33. SOLARI N, Gipponi M, Franco DS, Re F, et al
    Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma.
    Anticancer Res. 2016;36:6579-6583.
    PubMed     Text format     Abstract available


  34. YAN S, Holderness BM, Li Z, Seidel GD, et al
    Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.
    Anticancer Res. 2016;36:6449-6456.
    PubMed     Text format     Abstract available


  35. MANTSO T, Sfakianos AP, Atkinson A, Anestopoulos I, et al
    Development of a Novel Experimental In Vitro Model of Isothiocyanate-induced Apoptosis in Human Malignant Melanoma Cells.
    Anticancer Res. 2016;36:6303-6309.
    PubMed     Text format     Abstract available


    November 2016
  36. MARTON A, Kusz E, Kolozsi C, Tubak V, et al
    Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFkB Activation and Suppress Growth of A375 Human Melanoma.
    Anticancer Res. 2016;36:5743-5750.
    PubMed     Text format     Abstract available


    October 2016
  37. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


    September 2016
  38. BASNET A, Saad N, Benjamin S
    A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
    Anticancer Res. 2016;36:4795-8.
    PubMed     Text format     Abstract available


  39. DONIZY P, Biecek P, Halon A, Matkowski R, et al
    BILLCD8 - A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients.
    Anticancer Res. 2016;36:4739-47.
    PubMed     Text format     Abstract available


  40. RAICA M, Jitariu AA, Cimpean AM
    Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.
    Anticancer Res. 2016;36:4427-35.
    PubMed     Text format     Abstract available


    August 2016

  41. Melanoma.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    



  42. Genetics of Melanoma.
    Anticancer Res. 2016;36:4374.
    PubMed     Text format    


    July 2016
  43. LUO H, Umebayashi M, Doi K, Morisaki T, et al
    Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Anticancer Res. 2016;36:3585-9.
    PubMed     Text format     Abstract available


  44. CALIK J, Pula B, Piotrowska A, Wojnar A, et al
    Prognostic Significance of NOGO-A/B and NOGO-B Receptor Expression in Malignant Melanoma - A Preliminary Study.
    Anticancer Res. 2016;36:3401-7.
    PubMed     Text format     Abstract available


  45. TANG T, Eldabaje R, Yang L
    Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Anticancer Res. 2016;36:3229-41.
    PubMed     Text format     Abstract available


  46. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


  47. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Text format     Abstract available


    June 2016
  48. GORKA E, Fabo D, Gezsi A, Czirbesz K, et al
    Distance from Primary Tumor Is the Strongest Predictor for Early Onset of Brain Metastases in Melanoma.
    Anticancer Res. 2016;36:3065-9.
    PubMed     Text format     Abstract available


  49. YAN S, Coffing BN, Li Z, Xie H, et al
    Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
    Anticancer Res. 2016;36:2871-80.
    PubMed     Text format     Abstract available


    May 2016
  50. ORNAT M, Kobierzycki C, Grzegrzolka J, Pula B, et al
    SOX18 Expression in Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2379-83.
    PubMed     Text format     Abstract available


  51. ESPELI V, Ruegg E, Hottinger AF, Modarressi A, et al
    Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
    Anticancer Res. 2016;36:2359-64.
    PubMed     Text format     Abstract available


  52. KIM JK, Kang KA, Ryu YS, Piao MJ, et al
    Induction of Endoplasmic Reticulum Stress via Reactive Oxygen Species Mediated by Luteolin in Melanoma Cells.
    Anticancer Res. 2016;36:2281-9.
    PubMed     Text format     Abstract available


    April 2016
  53. WOJCIECHOWSKA-ZDROJOWY M, Szepietowski JC, Matusiak L, Dziegiel P, et al
    Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis.
    Anticancer Res. 2016;36:1591-7.
    PubMed     Text format     Abstract available


  54. HINTSALA HR, Jokinen E, Haapasaari KM, Moza M, et al
    Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
    Anticancer Res. 2016;36:1497-506.
    PubMed     Text format     Abstract available


    January 2016
  55. ADAMS S, Lin J, Brown D, Shriver CD, et al
    Ultraviolet Radiation Exposure and the Incidence of Oral, Pharyngeal and Cervical Cancer and Melanoma: An Analysis of the SEER Data.
    Anticancer Res. 2016;36:233-7.
    PubMed     Text format     Abstract available


    December 2015
  56. DECOSTER L, Vande Broek I, Neyns B, Majois F, et al
    Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
    Anticancer Res. 2015;35:6893-9.
    PubMed     Text format     Abstract available


  57. BARAK V, Leibovici V, Peretz T, Kalichman I, et al
    Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100beta.
    Anticancer Res. 2015;35:6755-60.
    PubMed     Text format     Abstract available


    November 2015
  58. KRAJSOVA I, Arenberger P, Lakomy R, Kubala E, et al
    Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
    Anticancer Res. 2015;35:6303-10.
    PubMed     Text format     Abstract available


  59. HU WP, Hsu CC, Wang YC, Senadi GC, et al
    Bis(phenylidenebenzeneamine)-1-disulfide Derivatives Induce Autophagy in Melanoma Cells Through a Mitochondria-mediated Pathway.
    Anticancer Res. 2015;35:6075-80.
    PubMed     Text format     Abstract available


    October 2015
  60. PAP M, Bator J, Szeberenyi J
    Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus.
    Anticancer Res. 2015;35:5401-6.
    PubMed     Text format     Abstract available


  61. PROVINCIALI M, Pierpaoli E, Bartozzi B, Bernardini G, et al
    Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand.
    Anticancer Res. 2015;35:5309-16.
    PubMed     Text format     Abstract available


  62. VETVICKA V, Vetvickova J
    Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells.
    Anticancer Res. 2015;35:5287-92.
    PubMed     Text format     Abstract available


    September 2015
  63. HAN SM, Park CW, Ahn JO, Park SC, et al
    Pro-apoptotic and Growth-inhibitory Effect of IFN-beta-Overexpressing Canine Adipose Tissue-derived Mesenchymal Stem Cells Against Melanoma Cells.
    Anticancer Res. 2015;35:4749-56.
    PubMed     Text format     Abstract available


    August 2015
  64. OTSUBO D, Yamashita K, Fujita M, Nishi M, et al
    Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
    Anticancer Res. 2015;35:4425-31.
    PubMed     Text format     Abstract available


    July 2015
  65. ZHANG L, Agarwal S, Shohet JM, Zage PE, et al
    CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.
    Anticancer Res. 2015;35:3787-92.
    PubMed     Text format     Abstract available


  66. ADINOLFI B, Carpi S, Romanini A, DA Pozzo E, et al
    Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells.
    Anticancer Res. 2015;35:3781-6.
    PubMed     Text format     Abstract available


    June 2015
  67. KUCERA R, Topolcan O, Treskova I, Kinkorova J, et al
    Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics.
    Anticancer Res. 2015;35:3537-41.
    PubMed     Text format     Abstract available


  68. ZHANG L, Xie Q, Shan SJ, Tabor MK, et al
    Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus.
    Anticancer Res. 2015;35:3185-91.
    PubMed     Text format     Abstract available


    May 2015

  69. BRAF Targets in Melanoma. Biological Mechanisms, Resistance, and Drug Delivery.
    Anticancer Res. 2015;35:3113.
    PubMed     Text format    


  70. WOZNIAK M, Sztiller-Sikorska M, Czyz M
    Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli.
    Anticancer Res. 2015;35:2747-58.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: